有证据表明,SCO-267的P450细胞染色体3A4介导的代谢激活SCO-267的证据
Cui Li1, Xiaokun Li2, Ali Fan3
1Department of Pharmacy, Henan Province Hospital of Chinese Medicine, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan Province, China.
Biopharmaceutics & drug disposition
|January 18, 2024
概括
糖尿病候选药物SCO-267通过CYP3A4进行生物激活,形成反应性中间体. 这些中间体使CYP3A失活,这表明存在潜在的安全问题,需要进一步调查.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 毒理学 毒理学 毒理学
背景情况:
- SCO-267是一种G蛋白结合受体40激动剂,正在开发用于2型糖尿病.
- 了解药物生物激活对于评估安全性和有效性至关重要.
研究的目的:
- 研究SCO-267.7的体外和体外生物激活潜力.
- 为了识别代谢物和阐明所涉及的代谢途径.
- 评估SCO-267对细胞染色体P450 3A (CYP3A) 活性的影响.
主要方法:
- 用肝脏显微体和谷氨 (GSH) 化SCO-267以确定GSH结合物.
- 将SCO-267给大鼠,并分析胆汁中的代谢物.
- 酶动力学研究以确定SCO-267对CYP3A活性的影响,使用丸激素作为探针基质.
主要成果:
- 在实验室中发现了三种SCO-267衍生的GSH合物 (M1-M3).
- 在大鼠胆中检测到两种GSH合物 (M1-M2) 和两种N-乙-氨酸合物 (M4-M5).
- SCO-267主要经历CYP3A4催化生物激活,产生氨胺和正中间体.
- SCO-267导致了依赖于度,时间和NADPH的CYP3A无活化,其KI = 4.91μM和kinact = 0.036分钟-1 .
- 谷氨 (GSH) 对CYP3A无活化有显著的保护,而可纳没有.
结论:
- SCO-267是由CYP3A4生物激活到反应性中间体 (氨胺,氨酸).
- 这些中间体负责观察到的CYP3A的失活.
- 生物激活途径表明有潜在的反应性代谢物形成,需要进一步评估体内安全性.
更多相关视频
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
13.8K
08:15Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis
Published on: February 3, 2022
3.2K
相关概念视频
Drug Metabolism: Phase I Reactions
3.3K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.3K
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Photochemical Electrocyclic Reactions: Stereochemistry
1.8K
The absorption of UV–visible light by conjugated systems causes the promotion of an electron from the ground state to the excited state. Consequently, photochemical electrocyclic reactions proceed via the excited-state HOMO rather than the ground-state HOMO. Since the ground- and excited-state HOMOs have different symmetries, the stereochemical outcome of electrocyclic reactions depends on the mode of activation; i.e., thermal or photochemical.
Selection Rules: Photochemical Activation
Selection Rules: Photochemical Activation
1.8K
